MA41251A - Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk - Google Patents

Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk

Info

Publication number
MA41251A
MA41251A MA041251A MA41251A MA41251A MA 41251 A MA41251 A MA 41251A MA 041251 A MA041251 A MA 041251A MA 41251 A MA41251 A MA 41251A MA 41251 A MA41251 A MA 41251A
Authority
MA
Morocco
Prior art keywords
thiéno
pyrrol
derivatives
erk inhibitors
erk
Prior art date
Application number
MA041251A
Other languages
English (en)
Other versions
MA41251B1 (fr
Inventor
Guillermo S Cortez
Sajan Joseph
Johnathan Alexander Mclean
William T Mcmillen
Michael John Rodriguez
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41251A publication Critical patent/MA41251A/fr
Publication of MA41251B1 publication Critical patent/MA41251B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
MA41251A 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk MA41251B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095185P 2014-12-22 2014-12-22
EP15823869.1A EP3237423B1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
PCT/US2015/065940 WO2016106029A1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one utilisés en tant qu'inhibiteurs de erk

Publications (2)

Publication Number Publication Date
MA41251A true MA41251A (fr) 2017-11-01
MA41251B1 MA41251B1 (fr) 2019-09-30

Family

ID=55135525

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41251A MA41251B1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk

Country Status (44)

Country Link
US (3) US9469652B2 (fr)
EP (1) EP3237423B1 (fr)
JP (1) JP6445701B2 (fr)
KR (1) KR101917972B1 (fr)
CN (1) CN107108648B (fr)
AR (1) AR102977A1 (fr)
AU (1) AU2015369983C1 (fr)
BR (1) BR112017011130A2 (fr)
CA (1) CA2966559C (fr)
CL (1) CL2017001514A1 (fr)
CO (1) CO2017005217A2 (fr)
CR (1) CR20170182A (fr)
CY (1) CY1121831T1 (fr)
DK (1) DK3237423T3 (fr)
DO (1) DOP2017000122A (fr)
EA (1) EA031659B1 (fr)
EC (1) ECSP17038500A (fr)
ES (1) ES2738406T3 (fr)
GT (1) GT201700134A (fr)
HR (1) HRP20191268T1 (fr)
HU (1) HUE045933T2 (fr)
IL (1) IL252065B (fr)
JO (1) JO3596B1 (fr)
LT (1) LT3237423T (fr)
MA (1) MA41251B1 (fr)
MD (1) MD3237423T2 (fr)
ME (1) ME03490B (fr)
MX (1) MX371206B (fr)
MY (1) MY178426A (fr)
NZ (1) NZ731531A (fr)
PE (1) PE20171043A1 (fr)
PH (1) PH12017501155A1 (fr)
PL (1) PL3237423T3 (fr)
PT (1) PT3237423T (fr)
RS (1) RS59015B1 (fr)
SG (1) SG11201704521SA (fr)
SI (1) SI3237423T1 (fr)
SV (1) SV2017005443A (fr)
TN (1) TN2017000233A1 (fr)
TR (1) TR201909887T4 (fr)
TW (1) TWI704151B (fr)
UA (1) UA119686C2 (fr)
WO (1) WO2016106029A1 (fr)
ZA (1) ZA201702786B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052096B8 (fr) 2013-10-03 2018-03-07 Kura Oncology, Inc. Inhibiteurs d'erk et méthodes d'utilisation
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
JP6322770B2 (ja) 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Ｅｒｋ阻害剤
CA3001799A1 (fr) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Composes benzolactames utilises en tant qu'inhibiteurs de proteine kinase
WO2018005234A1 (fr) * 2016-06-29 2018-01-04 Eli Lilly And Company Combinaison d'un composé inhibiteur d'erk1/2 avec la gemcitabine ou avec la gemcitabine et nab-paclitaxel pour utilisation dans le traitement du cancer du pancréas
WO2018081204A1 (fr) * 2016-10-26 2018-05-03 Li George Y N-(5-((4-éthylpipérazine-1-yl)méthyl) pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-méthyl-1h-benzo[d]imidazol-6-yl)pyrimidin-2-amine deutéré
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN111655690B (zh) 2017-11-24 2023-01-10 詹森药业有限公司 吡唑并吡啶酮化合物
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
CA3101117A1 (fr) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Composes heterocycliques utilises en tant qu'inhibiteurs de kinase, compositions comprenant le compose heterocyclique, et leurs procedes d'utilisation
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020197917A1 (fr) * 2019-03-27 2020-10-01 Eli Lilly And Company Sels de composé 5,6-dihydro-4h-thiéno[2,3-c]pyrrol-4-one utilisés en tant qu'inhibiteurs d'erk
CN113518779B (zh) * 2019-03-28 2024-03-15 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
BR112021018924A2 (pt) * 2019-03-29 2022-02-01 Jiangsu Hengrui Medicine Co Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CN113811303A (zh) * 2019-05-16 2021-12-17 伊莱利利公司 用于治疗brafv600e结直肠癌的erk1/2抑制剂与braf抑制剂和egfr抑制剂的三药组合
CN112457326B (zh) * 2019-09-06 2022-02-15 上海凌达生物医药有限公司 一类芳香杂环并内酰胺类化合物、制备方法和用途
EP4071152A4 (fr) 2019-12-06 2024-01-17 D3 Bio Wuxi Co Ltd Composé spiro servant d'inhibiteur d'erk et son application
CN110950876B (zh) * 2019-12-10 2021-08-17 上海凌达生物医药有限公司 一类呋喃并内酰胺类化合物、制备方法和用途
WO2021216777A1 (fr) * 2020-04-21 2021-10-28 The Trustees Of The Stevens Institute Of Technology Inhibiteurs d'erk pour thérapie anticancéreuse
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
WO2022068860A1 (fr) * 2020-09-29 2022-04-07 江苏恒瑞医药股份有限公司 Forme cristalline d'un dérivé pyrrolo-hétérocyclique et son procédé de préparation
KR20240024963A (ko) * 2021-06-28 2024-02-26 디3 바이오(우씨) 컴퍼니 리미티드 티아졸-락탐-스피로헤테로사이클릭 화합물 및 이의 적용
TW202332448A (zh) * 2021-11-15 2023-08-16 美商艾瑞斯卡公司 噻吩ulk1/2抑制劑及其用途
WO2023137297A2 (fr) * 2022-01-11 2023-07-20 Suvalent Therapeutics, Inc. Inhibiteurs de 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
CA2422371C (fr) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2478169C (fr) 2002-03-04 2013-04-16 Imclone Systems Incorporated Anticorps humains specifiques de kdr et leurs utilisations
CA2506773A1 (fr) * 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Derives d'heteroaryle pyrimidine utilises comme inhibiteurs de jak (janus kinase)
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2007053776A1 (fr) 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophène
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
CN102245600A (zh) * 2008-10-08 2011-11-16 百时美施贵宝公司 吡咯烷酮黑色素浓集激素受体-1拮抗剂
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CA2809662C (fr) * 2010-09-01 2019-04-16 Gilead Connecticut, Inc. Pyridazinones, leur procede de fabrication et leur procede d'utilisation
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
SI2820009T1 (en) * 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine / Threonine kinase inhibitors
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
JP6322770B2 (ja) * 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Ｅｒｋ阻害剤

Also Published As

Publication number Publication date
WO2016106029A1 (fr) 2016-06-30
US9526733B1 (en) 2016-12-27
ES2738406T3 (es) 2020-01-22
ME03490B (fr) 2020-01-20
CN107108648A (zh) 2017-08-29
AU2015369983C1 (en) 2019-02-21
IL252065B (en) 2020-08-31
KR101917972B1 (ko) 2018-11-12
UA119686C2 (uk) 2019-07-25
AR102977A1 (es) 2017-04-05
AU2015369983A1 (en) 2017-05-25
CA2966559C (fr) 2019-06-18
LT3237423T (lt) 2019-08-26
US20160375030A1 (en) 2016-12-29
EP3237423A1 (fr) 2017-11-01
IL252065A0 (en) 2017-07-31
DOP2017000122A (es) 2017-06-15
MX2017008242A (es) 2017-10-06
TR201909887T4 (tr) 2019-07-22
US9469652B2 (en) 2016-10-18
PE20171043A1 (es) 2017-07-19
EP3237423B1 (fr) 2019-06-05
PH12017501155B1 (en) 2017-11-27
BR112017011130A2 (pt) 2017-12-26
DK3237423T3 (da) 2019-07-22
CR20170182A (es) 2017-06-21
CN107108648B (zh) 2019-07-12
MY178426A (en) 2020-10-13
CO2017005217A2 (es) 2017-09-20
GT201700134A (es) 2018-11-23
HUE045933T2 (hu) 2020-01-28
HRP20191268T1 (hr) 2019-11-01
PL3237423T3 (pl) 2020-01-31
USRE48635E1 (en) 2021-07-13
CY1121831T1 (el) 2020-07-31
TWI704151B (zh) 2020-09-11
MA41251B1 (fr) 2019-09-30
MD3237423T2 (ro) 2019-11-30
CA2966559A1 (fr) 2016-06-30
ZA201702786B (en) 2019-02-27
SG11201704521SA (en) 2017-07-28
JO3596B1 (ar) 2020-07-05
EA031659B1 (ru) 2019-02-28
PT3237423T (pt) 2019-08-21
NZ731531A (en) 2018-12-21
ECSP17038500A (es) 2017-12-01
US20160176896A1 (en) 2016-06-23
JP2017538768A (ja) 2017-12-28
TN2017000233A1 (en) 2018-10-19
CL2017001514A1 (es) 2018-02-09
EA201791133A1 (ru) 2017-10-31
SV2017005443A (es) 2018-08-27
RS59015B1 (sr) 2019-08-30
KR20170083145A (ko) 2017-07-17
SI3237423T1 (sl) 2019-08-30
AU2015369983B2 (en) 2018-08-23
PH12017501155A1 (en) 2017-11-27
MX371206B (es) 2020-01-22
TW201632530A (zh) 2016-09-16
JP6445701B2 (ja) 2018-12-26

Similar Documents

Publication Publication Date Title
MA41251A (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MA43753A (fr) Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
MA45591A (fr) Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
IL256265B (en) 3-tetrazolyl-benzene-2,1-disulfonamide derivatives as metallo-beta-lactamase inhibitors
HK1253372A1 (zh) 作為bace1抑制劑的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3，4，5，6-四氫吡啶
EP3394068A4 (fr) Inhibiteurs de tdo2
MA40941A (fr) 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
HK1246779A1 (zh) 作為磷酸肌醇3-激酶抑制劑的色烯衍生物
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
MA42604A (fr) 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk